Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical, Inc. (NYSE: GMED) is a global musculoskeletal company in the surgical and medical instrument manufacturing industry. The GMED news page on Stock Titan aggregates coverage focused on the company’s musculoskeletal solutions, enabling technologies, and corporate developments that matter to investors and healthcare professionals.
News about Globus Medical often centers on quarterly and annual financial results, where the company reports worldwide net sales, U.S. and international performance, and non-GAAP metrics such as adjusted EBITDA, non-GAAP net income, and non-GAAP diluted earnings per share. These releases also discuss trends in its U.S. Spine business, contributions from acquisitions such as NuVasive and Nevro, and updates to revenue and earnings guidance.
Product and technology announcements are another key news category. Globus Medical has highlighted launches like the ANTHEM™ Elbow Fracture System within its trauma portfolio and additions to its Power Portfolio, including the DuraPro™ oscillating system with navigation and the Verzera™ high-speed drill system, which integrate with platforms such as ExcelsiusGPS™ and ExcelsiusHub™. These updates provide insight into the company’s efforts to advance spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
Investors can also follow corporate and legal developments, including leadership transitions at the executive level, share repurchase authorizations, and patent litigation outcomes related to expandable spinal fusion implants and other technologies. Earnings call schedules and webcast details are regularly announced, giving context on how management views business performance and strategic priorities.
By monitoring GMED news, readers can track how Globus Medical’s financial results, product pipeline, acquisitions, and intellectual property strategy evolve over time. Bookmark this page to access an organized stream of company-specific headlines and updates.
Globus Medical, Inc. (NYSE:GMED) will release its financial results for Q3 2021 on November 4, 2021, after market close. A teleconference discussing the results will follow at 4:30 p.m. ET, accessible to all interested parties. The company, based in Audubon, PA, specializes in musculoskeletal solutions and aims to promote healing in patients. For further details, visit their investor relations page at www.globusmedical.com/investors.
Globus Medical has filed a lawsuit against Life Spine for allegedly infringing on seven patents concerning expandable interbody spacer technology. The case, initiated in the District Court of Delaware, seeks injunctive relief and damages. CEO Dave Demski emphasized the importance of protecting their intellectual property, noting the company's substantial investment in research and the development of over 256 patents related to this technology. The firm aims to safeguard its advancements against competitors that produce infringing products.
Globus Medical announced participation in the 36th Annual Meeting of the North American Spine Society (NASS) from September 29 to October 2, 2021, in Boston. The company will showcase advancements in robotic spine and minimally invasive lateral lumbar surgery, including the Excelsius Lateral 360 procedure and the newly launched Excelsius3D intelligent imaging system, recently 510(k)-cleared by the FDA. This innovative system integrates cone-beam CT, fluoroscopy, and digital radiography for enhanced surgical imaging.
Globus Medical (NYSE: GMED) announced the first use of its ExcelsiusGPS® Cranial Solutions platform for robot-assisted Deep Brain Stimulation (DBS). The platform, designed for cranial procedures, enhances operational efficiency and reduces human error. Dr. Francisco Ponce successfully performed the initial DBS using this technology, emphasizing its intuitive design. The ExcelsiusGPS® Cranial Solutions integrates MRI preoperative planning and features the only Fluoroscopy-to-CT registration on the market, simplifying complex procedures.
Globus Medical (NYSE: GMED) announced on August 16, 2021, that its innovative Excelsius3D™ imaging system received 510(k) clearance from the U.S. FDA. This intelligent 3-in-1 platform integrates 360° cone-beam CT, fluoroscopy, and high-resolution radiography into a single solution, enhancing procedural efficiency. The system is designed for both adult and pediatric patients, facilitating detailed imaging. Globus Medical plans to ramp up production for a commercial launch in the fourth quarter.
Globus Medical, a leader in musculoskeletal solutions, reported impressive Q2 2021 financial results. Worldwide net sales soared to $251 million, a 68.6% increase from Q2 2020. GAAP net income reached $41.5 million (16.6% of net sales), marking a 299.4% rise. GAAP diluted EPS improved to $0.40, while non-GAAP diluted EPS surged to $0.56, up 691.2%. The company has increased its full-year sales guidance from $925 million to $950 million. As of June 30, 2021, Globus maintains a strong cash position of $914.2 million and remains debt-free.
Globus Medical, Inc. (NYSE:GMED) will release its financial results for Q2 2021 after market close on August 4, 2021. A teleconference will follow at 4:30 p.m. ET, allowing stakeholders to discuss performance. The company, founded in 2003, specializes in musculoskeletal solutions and emphasizes its commitment to innovation and surgeon support. Interested parties may access the teleconference by phone or via a webcast on their investor website. The details, including access numbers for U.S. and international participants, are provided in the release.
Globus Medical (NYSE: GMED) announced the successful use of its ExcelsiusGPS Robotic Navigation system in over 20,000 spine procedures. This innovative platform enhances surgical accuracy, reduces radiation exposure, and saves operating time.
Dr. Roland Kent highlighted significant decreases in operative times while using the system for various spine surgeries. The platform's multifunctionality and real-time information facilitate accurate trajectory alignment, addressing gaps in existing navigation technologies.
Globus Medical, Inc. (NYSE: GMED) reported strong financial results for Q1 2021, with worldwide net sales reaching $227.3 million, a 19.3% increase from Q1 2020. GAAP net income soared to $45.3 million, or 19.9% of net sales, marking a 74.7% year-over-year increase. The GAAP diluted EPS was $0.44, up from $0.25 a year prior. The company raised its 2021 net sales guidance from $880 million to $925 million.
Strong growth in the U.S. Spine business and an 86% increase in Enabling Technologies revenue contributed to these results.
Globus Medical, Inc. (NYSE:GMED) plans to release its financial results for the first quarter ending March 31, 2021, on May 4, 2021, after market close. The company will host a teleconference at 4:30 p.m. ET to discuss its performance with investors. Participants can join via dial-in numbers provided or access the webcast through the company’s website. The audio archive will be available until May 11, 2021. Globus Medical, established in 2003, focuses on musculoskeletal solutions and aims to support patient healing.